Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction
Authors:
Open Access
- 1 November 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (9) , 3168-3174
Abstract
A variable degree of humoral immunodeficiency is a common feature in patients with B-cell chronic lymphocytic leukemia (B-CLL). The aim of this study was to explore the possibility that B-CLL cells play a direct role in this phenomenon. To this end, patients' bone marrow (BM) immunoglobulin (Ig)-secreting cells were cocultured with autologous purified B-CLL cells. The results show that tumoral cells inhibited the spontaneous IgG secretion by BM plasma cells, and this effect increased after PMA-induction of B-CLL cells. This inhibitory process was proportional to the number of B-CLL cells added and depended on cellular contact. Adhesion molecules did not appear to be involved in the cellular interaction, because the inclusion of blocking antibody to a variety of these proteins did not reverse the inhibitory phenomenon. However, the addition of monoclonal antibody that blocked the function of either CD95 or CD95L clearly reversed B-CLL cell inhibition on autologous BM plasma cells. These latter cells were shown to express CD95, and B-CLL cells contained detectable quantities of CD95L at the level of messenger RNA and protein. Annexin V–binding experiments revealed increased apoptosis of BM Ig-secreting cells when cocultured with autologous B-CLL cells. Finally, this inhibitory phenomenon might be operative in vivo because (a) there was a good correlation between the intensity of the inhibitory effect in vitro and the serum IgG level exhibited by every patient and (b) B-CLL cells also inhibited in vivo antigen-induced IgG-tetanus toxoid–secreting cells obtained from normal immunized subjects. Collectively, these data suggest that B-CLL cells inhibit autologous CD95-bearing Ig-secreting cells by the interaction with CD95L present on B-CLL cells and, hence, contribute to the state of humoral immunodeficiency that occurs in these patients.Keywords
This publication has 27 references indexed in Scilit:
- Death Receptors: Signaling and ModulationScience, 1998
- Regulatory role of CD95 ligation on human B cells induced in vivo capable of spontaneous and highrate Ig secretionEuropean Journal of Immunology, 1997
- Metalloproteinase-mediated release of human Fas ligand.Journal of Experimental Medicine, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Essential role of tumor necrosis factor‐α in the differentiation of human tonsil in vivo induced B cells capable of spontaneous and high‐rate immunoglobulin secretionEuropean Journal of Immunology, 1993
- The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosisCell, 1991
- Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working groupAmerican Journal of Hematology, 1988
- Rheumatoid Factor Secretion from Human Leu-1 + B CellsScience, 1987
- Clinical Correlations with Immunoglobulin Levels in Chronic Lymphatic Leukaemia§Australian and New Zealand Journal of Medicine, 1972
- Immunological Deficiency Disorders Associated with Chronic Lymphocytic Leukemia and Multiple Myeloma*Journal of Clinical Investigation, 1964